<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200708048050N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-08</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of zinc supplementation (Zn) in patients receiving methadone maintenance treatment</public_title>
      <acronym></acronym>
      <scientific_title>The effect of zinc supplementation (Zn) on metabolic profile and expression of IL10, PPARγ, NRF2 genes in methadone maintenance patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49521</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: How to randomize with a simple method and use random numbers created by computer software (Stat Trek software) will be done. In this method, the computer selects random numbers. By considering numbers for two groups, randomization is done. For example, even numbers will be in the intervention group and odd numbers will be in the control group, Blinding description: Placebo has been used for blinding. Researchers and blind patients will be trained by a staff member until the final analysis.</study_design>
      <phase>3</phase>
      <hc_freetext>addiction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 30 mg International Zinc Supplement (Jalinous), orally daily for 12 weeks. Intervention 2: Control group: Placebo (Jalinous), every day of the week, orally for 12 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I haven't decided yet - the release schedule is still unknown</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azam Ghasemi Nejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghotbe Ravandi Boulevard, Kashan</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8814187159</zip>
        <telephone>+98 31 7504687</telephone>
        <email>samiraghasemineghad@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nejat Khairipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghotbe Ravandi Boulevard, Kashan</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8814187159</zip>
        <telephone>+98 31 5562 0875</telephone>
        <email>nejatkh.bio@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients treated with methadone maintenance in the age range of 30 to 60 years</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Positive urinary test for morphine, methamphetamine and cannabis
Do not have a specific disease
Zinc consumption in the last 3 months
High blood pressure
Consumption of psychiatric and neurological drugs during the study
Digestive problems and side effects of zinc consumption
Consumption of iron supplements</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F17.210</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>مواد مخدر٬ سیگار٬ اعتیاد</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 30 mg International Zinc Supplement (Jalinous), orally daily for 12 weeks.</i_keyword>
      <i_keyword>Control group: Placebo (Jalinous), every day of the week, orally for 12 weeks</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Beck Depression Inventory.</prim_outcome>
      <prim_outcome>Depression. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Beck Depression Inventory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Total serum cholesterol. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Clinical laboratory kit.</sec_outcome>
      <sec_outcome>HDL-C Serum. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Clinical laboratory kit.</sec_outcome>
      <sec_outcome>Serum triglyceride. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Clinical laboratory kit.</sec_outcome>
      <sec_outcome>Fasting blood sugar. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Enzymatic.</sec_outcome>
      <sec_outcome>Insulin. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Eliza.</sec_outcome>
      <sec_outcome>Insulin sensitivity. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Formula calculation.</sec_outcome>
      <sec_outcome>Insulin resistance. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Formula calculation.</sec_outcome>
      <sec_outcome>Total Glutathione. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Spectrophotometry.</sec_outcome>
      <sec_outcome>Malone di aldehyde. Timepoint: At the beginning of the study and 12 weeks after the interventio. Method of measurement: Spectrophotometry.</sec_outcome>
      <sec_outcome>Expressed levels of PPAR-γ. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.</sec_outcome>
      <sec_outcome>Expressed levels of IL-10. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.</sec_outcome>
      <sec_outcome>Expressed levels of NRF2. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: PCR.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-17</approval_date>
        <contact_name>Kashan University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Ghotbe Ravandi Boulevard, Kashan kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
